My research in cancer biology, specifically focused on glioblastoma multiforme (GBM), encompasses a comprehensive approach involving patient-derived models for in vivo and in vitro validation of genetic alterations and drug discovery. This work is crucial for understanding the molecular mechanisms driving GBM progression and identifying effective therapeutic strategies.
In vitro, I conduct detailed investigations of genetic alterations implicated in GBM using cell lines derived from PDX models. Techniques such as sh/siRNA orCRISPR/Cas9 genome editing, silencing and sequensing enable precise characterization of genetic drivers and tumor vulnerabilities. This work helps identify novel therapeutic targets and assesses the efficacy of potential drugs.
Additionally, I work extensively with mouse models to evaluate the effects of promising treatments on GBM progression and treatment outcomes. These preclinical studies provide crucial insights into the biology of GBM and inform the development of innovative therapeutic strategies aimed at improving patient outcomes.
Overall, my research in GBM integrates diverse methodologies—from patient-derived models to genetic characterization and drug screening—in pursuit of advancing our understanding of this devastating disease and developing innovative therapeutic interventions. This work underscores the importance of translational research in bridging the gap between benchside discoveries and clinical impact in oncology.
My research in cancer biology, specifically focused on glioblastoma multiforme (GBM), encompasses a comprehensive approach involving patient-derived models for in vivo and in vitro validation of genetic alterations and drug discovery. This work is crucial for understanding the molecular mechanisms driving GBM progression and identifying effective therapeutic strategies.
In vitro, I conduct detailed investigations of genetic alterations implicated in GBM using cell lines derived from PDX models. Techniques such as sh/siRNA orCRISPR/Cas9 genome editing, silencing and sequensing enable precise characterization of genetic drivers and tumor vulnerabilities. This work helps identify novel therapeutic targets and assesses the efficacy of potential drugs.
Additionally, I work extensively with mouse models to evaluate the effects of promising treatments on GBM progression and treatment outcomes. These preclinical studies provide crucial insights into the biology of GBM and inform the development of innovative therapeutic strategies aimed at improving patient outcomes.
Overall, my research in GBM integrates diverse methodologies—from patient-derived models to genetic characterization and drug screening—in pursuit of advancing our understanding of this devastating disease and developing innovative therapeutic interventions. This work underscores the importance of translational research in bridging the gap between benchside discoveries and clinical impact in oncology.